Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.62|
|52 Week High||AU$0.47|
|52 Week Low||AU$0.93|
|1 Month Change||16.98%|
|3 Month Change||29.17%|
|1 Year Change||-25.75%|
|3 Year Change||-42.86%|
|5 Year Change||-12.68%|
|Change since IPO||-86.52%|
Recent News & Updates
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|CYP||AU Biotechs||AU Market|
Return vs Industry: CYP underperformed the Australian Biotechs industry which returned 2.5% over the past year.
Return vs Market: CYP underperformed the Australian Market which returned 21.1% over the past year.
Stable Share Price: CYP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CYP's weekly volatility (7%) has been stable over the past year.
About the Company
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model.
Cynata Therapeutics Fundamentals Summary
|CYP fundamental statistics|
Is CYP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYP income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.054|
|Net Profit Margin||-497.38%|
How did CYP perform over the long term?See historical performance and comparison
Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CYP is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: CYP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYP is good value based on its PB Ratio (3.1x) compared to the AU Biotechs industry average (4.8x).
How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cynata Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cynata Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYP is currently unprofitable.
Growing Profit Margin: CYP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: CYP has a negative Return on Equity (-27.1%), as it is currently unprofitable.
How is Cynata Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CYP's short term assets (A$27.3M) exceed its short term liabilities (A$1.6M).
Long Term Liabilities: CYP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CYP is debt free.
Reducing Debt: CYP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CYP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.2% each year
What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CYP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ross MacDonald (63 yo)
Dr. Ross Alexander MacDonald, Ph D., Grad Dip in Bus Admin serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (formerly Eco Quest Limited). Dr. MacDonald served as t...
CEO Compensation Analysis
Compensation vs Market: Ross's total compensation ($USD679.13K) is above average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Ross's compensation has increased whilst the company is unprofitable.
Experienced Board: CYP's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.3%.
Cynata Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Cynata Therapeutics Limited
- Ticker: CYP
- Exchange: ASX
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$88.115m
- Shares outstanding: 143.28m
- Website: https://www.cynata.com
- Cynata Therapeutics Limited
- 100 Cubitt Street
- Level 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 07:04|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.